Developmental Cancer Therapeutics Members
Ajay Goel, Ph.D., M.S., is a professor researching molecular pathogenesis of human gastrointestinal cancers and its relationship to early detection of cancer, cancer prevention and cancer therapeutics at City of Hope, near Los Angeles.
David Horne, Ph.D., vice provost and deputy director of Beckman Research Institute of City of Hope and dean of faculty affairs, helps shape the scientific and educational vision of City of Hope with his research expertise in medicinal chemistry, drug development and molecular medicine.
Linda Malkas, Ph.D., is a professor in the Department of Molecular Diagnostics & Experimental Therapeutics at Beckman Research Institute of City of Hope.
Erminia Massarelli, M.D., Ph.D., M.S., is the co-director of the Lung Cancer and Thoracic Oncology Program, an associate professor in the Ddepartment of Medical Oncology & Therapeutics Research at City of Hope. She specializes in lung and head and neck cancers.
Sumanta Kumar Pal, M.D., is an internationally recognized leader in the area of genitourinary cancers. He is the co-director of City of Hope's Kidney Cancer Program and is the head of the kidney and bladder cancer disease team at the institution.
Russell Rockne, Ph.D. is the director of the Division of Mathematical Oncology in the Department of Computational and Quantitative Medicine at Beckman Research Institute of City of Hope.
Ravi Salgia M.D., Ph.D., is the Arthur & Rosalie Kaplan Chair in Medical Oncology at City of Hope and an expert in the study and treatment of lung cancer, mesothelioma, thoracic and thymic malignancies and bronchial carcinoids.
Nagarajan Vaidehi, Ph.D., chairs the Department of Computational and Quantitative Medicine and is associate director for Informatics and Computational Biomedicine at City of Hope, near Los Angeles. The Vaidehi lab develops physics-based computational methods to study the structure, function and
Victoria M. Villaflor, M.D., is a medical oncologist and section chief of head and neck medical oncology in the Department of Medical Oncology & Therapeutics Research, specializing in cancers of the “aerodigestive” system: head and neck cancer, lung cancer, esophageal cancer and other malignancies